Research Overview
Origin as a splice variant
The IGF-1 gene produces several transcripts through alternative splicing. In rodents the mechano-sensitive form is designated IGF-1 Eb and in humans IGF-1 Ec; both carry a distinct C-terminal extension known as the E-domain. Researchers isolated the final 24 residues of that domain and named the resulting peptide Mechano Growth Factor. Expression studies have consistently reported that the Ec transcript is upregulated in skeletal muscle after resistance loading, stretch or injury, then returns toward baseline over the following days.
Published cell and animal work has focused on a few recurring questions:
- Whether the isolated E-domain peptide promotes proliferation of myoblasts and satellite cells in culture without pushing them toward terminal differentiation.
- Whether the peptide acts through an unidentified receptor, since the isolated E-domain shows little affinity for the IGF-1 receptor.
- Effects reported in cardiac and neural tissue models, where the same splice variant has been detected after stress.
Pharmacokinetic caveats
The most frequently noted limitation in the MGF literature is stability. Unmodified MGF is cleared rapidly and is degraded quickly in serum, which complicates any attempt to translate in-vitro findings into whole-animal designs. This is the direct reason PEGylated MGF was developed, and comparisons between the two are a common experimental control.
